{
    "body": "Which receptors are targeted by suvorexant?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24215799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24488306", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24680372", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23024835", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23964859", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22920041", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25489915", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25147058", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22725839", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23197752", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23692283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25407283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23359095", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25197807", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25533960", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24757363", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25397996", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24942635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21528938", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25227290", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23282091", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25291725", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21473737", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23731216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23372274", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24550770"
    ], 
    "ideal_answer": [
        "Suvorexant is a potent, selective, and orally bioavailable antagonist of orexin 1 receptor and orexin 2 receptor currently under clinical investigation as a novel therapy for insomnia."
    ], 
    "exact_answer": [
        [
            "orexin 1"
        ], 
        [
            "orexin 2"
        ]
    ], 
    "type": "list", 
    "id": "54fc9ca16ad7dcbc12000006", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 245, 
            "text": "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical trials in volunteers and primary insomnia patients. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964859", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 130, 
            "offsetInEndSection": 267, 
            "text": "Several such compounds have entered into clinical development, including the dual orexin receptor antagonists, suvorexant and almorexant.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692283", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 17, 
            "offsetInEndSection": 119, 
            "text": " Suvorexant (MK-4305) is an orexin receptor antagonist being developed for the treatment of insomnia. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23372274", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 741, 
            "offsetInEndSection": 944, 
            "text": "Indeed, phase III clinical trials were completed last year of suvorexant, a non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and demonstrate promising results.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359095", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 105, 
            "offsetInEndSection": 327, 
            "text": "METHODS: We evaluated suvorexant, an orexin receptor antagonist, for treating patients with primary insomnia in a randomized, double-blind, placebo-controlled, 2-period (4 weeks per period) crossover polysomnography study.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23197752", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 138, 
            "text": "Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024835", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 550, 
            "offsetInEndSection": 755, 
            "text": "Merck's suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920041", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 102, 
            "text": "A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22725839", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 173, 
            "text": "Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305).", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21528938", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 264, 
            "text": "The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21528938", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 406, 
            "offsetInEndSection": 578, 
            "text": "Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473737", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 167, 
            "text": "Suvorexant is a pharmacologically novel dual antagonist of orexin receptors OX1R and OX2R, which has an effect that promotes sleep by reducing arousal and wakefulness.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25291725", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 736, 
            "offsetInEndSection": 940, 
            "text": " Indeed, phase III clinical trials were completed last year of suvorexant, a non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and demonstrate promising results.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359095", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 202, 
            "offsetInEndSection": 506, 
            "text": " In order to understand the differential contribution of both receptors in regulating sleep/wakefulness states we compared the pharmacological effects of a newly developed OX2R antagonist (2-SORA), Compound 1 m (C1 m), with those of a dual orexin receptor antagonist (DORA), suvorexant, in C57BL/6J mice.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24550770", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 73, 
            "text": "Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21473737", 
            "endSection": "title"
        }
    ]
}